Meeting
2019 ASCO Annual Meeting
NEO-adjuvant chemo-immunotherapy for the treatment of STAGE IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study—Final data of patients who underwent surgical assessment.
Authors
Mariano Provencio
Hospital Puerta de Hierro de Majadahonda, Madrid, Spain
Mariano Provencio , Ernest Nadal , Amelia Insa , Rosario Garcia-Campelo , Joaquín Casal Rubio , Manuel Domine , Margarita Majem , Delvys Rodriguez-Abreu , Alex Martinez Marti , Manuel Cobo , Guillermo Lopez-Vivanco , Elvira del Barco , Reyes Bernabé , Nuria Vinolas , Isidoro Barneto , Santiago Viteri , Paloma Martín-Martorell , Maria Jove , Fabio Franco , Bartomeu Massuti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT 03081689
Citation
J Clin Oncol 37, 2019 (suppl; abstr 8509)
DOI
10.1200/JCO.2019.37.15_suppl.8509
Abstract #
8509
Poster Bd #
265
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC.
First Author: Ralph Zinner
Poster
2020 ASCO Virtual Scientific Program
Peripheral blood T-cell receptor immune repertoire characterization of resectable stage IIIA non-small cell lung cancer patients receiving neo-adjuvant chemo-immunotherapy treatment from NADIM study.
First Author: Alberto Cruz Bermudez
Poster
2018 ASCO Annual Meeting
Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.
First Author: Mariano Provencio-Pulla
Poster
2024 ASCO Annual Meeting
Efficacy and surgical safety of sequential surgical resection after neoadjuvant chemoimmunotherapy for unresectable stage III NSCLC.
First Author: Yana Qi